News Snapshot:
Merck plans to apply for emergency use authorization of its molnupiravir antiviral pill in the U.S. by the end of 2021. (Photo courtesy of Merck) © Kyodo NORIYUKI TAKADA, Nikkei staff writer September 24, 2021 06:26 JST | Japan Copy Copied TOKYO -- Clinical trials for a COVID-19 pill have kicked off across the world, as pharmaceutical companies work on a simpler and more affordable way to treat patients and help finally bring the pandemic under control. U.S.-based Merck is working with startup Ridgeback Biotherapeutics on an oral antiviral treatment called molnupiravir. A final Phase 3 trial for the drug...
